This study compares two treatments, EYP-1901 and Aflibercept, for diabetic macular edema (DME), a condition where fluid builds up in the eye due to diabetes. Patients who have been treated before or are new to treatment can join if they have DME in at least one eye. Their vision must meet certain standards, measured with charts that display letters of different sizes. For example, a score of 35 letters means they see as well as someone with 20/200 vision, while 78 letters mean 20/32 vision. Those who have been treated before should have had at least one anti-VEGF (a type of eye medicine) injection in the past year. They should not have received this treatment less than 12 weeks before the study starts.

• Participants will be randomly assigned to receive either EYP-1901 or Aflibercept, but neither they nor the doctors will know which one.
• The study requires multiple visits to the clinic for evaluations and treatments.
• Participants might be eligible for compensation for their time and travel.